Home › Lung Diseases › NCT04164173

Hyperinflation Respiratory Therapies in Cardiac Surgery Patients

Hyperinflation Respiratory Therapies in Cardiac Surgery Patients: A Randomized, Observer-Blinded, Prospective Clinical Trial

Who can join

Ages 18 to 80 · All sexes

Inclusion Criteria:

1. Age 18 years and older
2. Admitted to Cardiovascular ICU (CVICU) after coronary artery bypass grafting (CABG), isolated valve repair/replacement, or CABG + valve repair/replacement
3. Cardiac surgery performed via median sternotomy

Exclusion Criteria:

1. BMI\>40
2. Refusal to be consented
3. Prior or current lung transplant patients

About the study

The purpose of this prospective randomized clinical trial is to evaluate three different types of hyperinflation respiratory therapies, Intermittent Positive Pressure Breathing (IPPB), Intermittent positive end expiratory pressure (EzPAP), Metaneb. Investigators will examine which hyperinflation therapy provides better lung expansion and may improve lung recovery after surgery.

What is being tested

• EzPAP (device)
• Metaneb (device)
• Intermittent Positive Pressure Breathing (IPPB) (device)

Sponsor: University of Texas Southwestern Medical Center · Participants: 324 · Started: Jun 15, 2020

Contact the study team

• Jaffer Odeh, MD · Phone: 214-786-1067
• Emily Melikman, RN · Phone: 214-645-7011

Official record on ClinicalTrials.gov — NCT04164173

Locations in the U.S.

Conditions

• Lung Diseases
• After Surgery

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.